With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.
Researchers have developed a DNA-based therapy that targets the PCSK9 gene to lower cholesterol naturally. Using polypurine ...
A collaborative research group has developed a novel therapeutic candidate that may improve the prognosis of severe cutaneous ...
The decision follows phase 3 trial data showing the immunotherapy cut disease recurrence or death risk by 68% in patients ...
Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone Repatha is Now the First and Only ...
A preclinical study presented at the 32nd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), held in ...
Phase III trial data support obicetrapib's lipid controlling effects in high-risk individuals without sufficient response to other lipid-lowering therapies. Obicetrapib is a highly selective CETP ...
Preclinical study showed PDIA1 and PDIA5 protect cells from oxidative stress, maintain mitochondrial function, and are ...
Even the launch of generic versions of heart failure blockbuster Entresto and Trump's threats to cut drug prices won't overshadow the strong performance of Novartis AG's oncology franchise. So, sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback